Metabolic Effects of 5α-Reductase Inhibition in Humans
July 2013
in “
Edinburgh Research Archive (University of Edinburgh)
”
Studysummary This study found that inhibiting 5αR1 with dutasteride leads to peripheral insulin resistance and increased body fat in men, which may have implications for its use in treating benign prostatic hyperplasia.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The study investigated the metabolic effects of 5α-reductase inhibitors, specifically focusing on dutasteride and finasteride, in a sample of 46 men over 3 months. It was found that dutasteride, which inhibits both 5αR1 and 5αR2, led to decreased peripheral insulin sensitivity and increased body fat, while hepatic insulin sensitivity remained unchanged. In contrast, finasteride, which only inhibits 5αR2, did not have these effects. Additionally, both inhibitors caused subtle dysregulation of the HPA axis, more so with dutasteride, though these changes were largely compensated for. The study highlighted potential metabolic implications for patients using dutasteride for benign prostatic hyperplasia.
